Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer’s Retacrit Finally Clears US FDA, But Biosimilar’s Launch Date Is Still Unclear

Executive Summary

First biosimilar of Epogen/Procrit might launch this year, but timing of market entry will depend on many factors, including ongoing patent litigation with Amgen in Delaware federal court.


Related Content

US FDA's Biosimilars Program: Five Years In, Complete Response Letters Still Outnumber Approvals
Epogen Biosimilar Jury Verdict May Ignite New 'Safe Harbor' Battle
Pfizer v. J&J Sets Stage For Biosimilar Showdown Over Exclusive Contracts
Pfizer’s EPO Biosimilar Stalls In US On Hospira Compliance Woes
Biosimilar Denied: Hospira's Retacrit Could Head Back To FDA In First Half 2016


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts